NCT07131956 Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
| NCT ID | NCT07131956 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Erlangen-Nürnberg Medical School |
| Condition | Prostate Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-12 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-12 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
Eligibility Criteria
Inclusion Criteria Arm 1: * Primary treatment with I-125 seeds or HDR-BT * No previous treatment for prostate cancer * Age ≥ 18 years Inclusion Criteria Arm 2: * HDR- or PDR-BT * No radiation therapy within three months before salvage treatment * Complete documentation available on previous treatment for prostate cancer * No history of prostatectomy * Age ≥ 18 years Exclusion Criteria: * Pre-existent auto-immune disease * patients under bloodthinning medication * substance abuse
Contact & Investigator
Claudia Schweizer, MD
PRINCIPAL INVESTIGATOR
Strahlenklinik Universitätsklinikum Erlangen
Frequently Asked Questions
Who can join the NCT07131956 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07131956 currently recruiting?
Yes, NCT07131956 is actively recruiting participants. Contact the research team at claudia.schweizer@uk-erlangen.de for enrollment information.
Where is the NCT07131956 trial being conducted?
This trial is being conducted at Augsburg, Germany, Erlangen, Germany, Munich, Germany.
Who is sponsoring the NCT07131956 clinical trial?
NCT07131956 is sponsored by University of Erlangen-Nürnberg Medical School. The principal investigator is Claudia Schweizer, MD at Strahlenklinik Universitätsklinikum Erlangen. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.